U.S. MarketsSeptember 15 at 10:51 AM

Gilead (GILD) expects its first weekly oral HIV treatment, based on islatravir, to launch next year; to expand beyond Biktarvy and targets a market where c. 20% of treated patients switch annually

StockNow breaking-news AI analysis

Gilead expects to launch its first weekly oral islatravir HIV regimen next year, targeting an annual 20% patient switching market to expand beyond its core Biktarvy franchise.

1 stocks

GILDGilead Sciences Inc$145.32Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Gilead (GILD) expects its first weekly oral HIV treatment, based on islatravir, to launch next year; to expand beyond Biktarvy and targets a market where c. 20% of treated patients switch annually

What do investors think?

Today's market highlights

US ADP Employment Change Weekly 16.25K (Prev. 12K)

Libya's NOC says production and operations have been suspended in 3 oil fields after a valve was closed on the Al-Hamada-Zawiya pipeline, may need to declare force majeure if its remains closed

Saudi Arabia is reportedly informing some European oil refiners that their Sep' loading of crude cargoes are cancelled, according to sources

Gilead (GILD) expects its first weekly oral HIV treatment, based on islatravir, to launch next year; to expand beyond Biktarvy and targets a market where c. 20% of treated patients switch annually

Related stocks

What do investors think?

Today's market highlights

US ADP Employment Change Weekly 16.25K (Prev. 12K)

Libya's NOC says production and operations have been suspended in 3 oil fields after a valve was closed on the Al-Hamada-Zawiya pipeline, may need to declare force majeure if its remains closed

Saudi Arabia is reportedly informing some European oil refiners that their Sep' loading of crude cargoes are cancelled, according to sources